Skip to Content

Join the 'Xeljanz' group to help and get support from people like you.

Xeljanz News

Pfizer Announces U.S. FDA Approves Xeljanz (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis

Posted 1 Jun 2018 by Drugs.com

Wednesday, May 30, 2018 - Pfizer Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved Xeljanz (tofacitinib) 10 mg twice-daily (BID) for at least eight weeks, followed by Xeljanz 5 mg BID or 10 mg BID, for the treatment of adult patients in the U.S. with moderately to severely active ulcerative colitis (UC).1 “Ulcerative colitis is a chronic inflammatory b ...

Xeljanz (Tofacitinib) Approved for Ulcerative Colitis

Posted 30 May 2018 by Drugs.com

WEDNESDAY, May 30, 2018 – U.S. Food and Drug Administration approval of Xeljanz (tofacitinib) has been expanded to include adults with active moderate-to-severe ulcerative colitis, the agency said Wednesday. Ulcerative colitis (UC) is a chronic inflammatory bowel disease, characterized by recurring flares of abdominal pain and bloody diarrhea. Symptoms also may include fatigue, weight loss and ...

New Combination Treatment Could Be 'Breakthrough' for Vitiligo Skin Condition

Posted 5 Feb 2018 by Drugs.com

MONDAY, Feb. 5, 2018 – Doctors have discovered a combination of treatments that can return color to skin that has been lightened by vitiligo – the skin disease that turned Michael Jackson's skin white. The new therapy includes the oral medication Xeljanz (tofacitinib) – a drug already approved for use in rheumatoid arthritis patients that dampens the body's immune response – and ultraviolet-B ...

Pfizer Announces FDA Approval of Xeljanz (tofacitinib) and Xeljanz XR for the Treatment of Active Psoriatic Arthritis

Posted 10 Jan 2018 by Drugs.com

December 14, 2017 - Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has approved Xeljanz 5 mg twice daily (BID) and Xeljanz XR (tofacitinib) extended release 11 mg once daily (QD) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying ...

Arthritis Drug Shows Promise for Ulcerative Colitis

Posted 4 May 2017 by Drugs.com

WEDNESDAY, May 3, 2017 – A new study finds that people with moderate to severe ulcerative colitis who haven't done well on other treatments may find relief with Xeljanz (tofacitinib), a drug currently used to treat arthritis. Ulcerative colitis is a chronic inflammatory bowel disease. It affects about 700,000 Americans, according to the Crohn's and Colitis Foundation (CCF). The illness causes ...

Early Treatment Equals Better Results for Rheumatoid Arthritis

Posted 25 Apr 2017 by Drugs.com

TUESDAY, April 25, 2017 – Treating rheumatoid arthritis early may make for better outcomes, a new study suggests. Patients who were treated within six months of developing the first signs of the autoimmune disease did better in the long run and were less likely to suffer early death, British researchers found. The findings stem from an analysis of more than 600 patients who were initially ...

Could a Germ Link Gum Disease, Rheumatoid Arthritis?

Posted 15 Dec 2016 by Drugs.com

THURSDAY, Dec. 15, 2016 – A specific germ may help explain the long-noticed connection between gum disease and rheumatoid arthritis, a new study suggests. The discovery might also point to the potential origins of the painful joint illness. "If we're right, this will totally change the view of rheumatoid arthritis and treatment of patients," said study co-author Dr. Felipe Andrade. But, Andrade, ...

Arthritis Drug May Help With Type of Hair Loss

Posted 22 Sep 2016 by Drugs.com

THURSDAY, Sept. 22, 2016 – For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests. Alopecia areata is an autoimmune disease that causes patchy or complete hair loss, including on the head, body, eyebrows and eyelashes. Researchers found that more than 50 percent of 66 patients treated ...

Pfizer Announces FDA Approval of Xeljanz XR (tofacitinib citrate), the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis

Posted 25 Feb 2016 by Drugs.com

February 24, 2016 – Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Xeljanz XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX). Xeljanz XR is the first and only once-daily oral ...

Drugs Used in Cancer, Arthritis May Help Fight Hair Loss

Posted 23 Oct 2015 by Drugs.com

FRIDAY, Oct. 23, 2015 – Two drugs – one approved for use in arthritis and the other approved for cancer – may also hold potential for boosting hair growth, new animal research suggests. "The ultimate potential is a very effective topical product to rub on the scalp to help with all types of hair loss," said Dr. Luis Garza, an associate professor of dermatology at Johns Hopkins School of ...

Drug for Rheumatoid Arthritis May Also Help Ease Vitiligo

Posted 24 Jun 2015 by Drugs.com

WEDNESDAY, June 24, 2015 – It's only been tested in one patient so far, but researchers report that a drug for rheumatoid arthritis may be a promising treatment for the discoloring skin condition known as vitiligo. Vitiligo is characterized by a disfiguring loss of pigmentation in skin. Most notably, pop star Michael Jackson suffered from the disorder much of his adult life. According to the ...

Gene Discoveries Could Help Rheumatoid Arthritis Treatment

Posted 28 Apr 2015 by Drugs.com

TUESDAY, April 28, 2015 – Genetic variations may hold clues to rheumatoid arthritis – suggesting not only who will develop the painful condition, but also predicting its severity and even who might die from it, a new study says. "Genetic factors predisposing to disease, to disease severity, and response to treatment will allow tailoring treatment to individual patients' needs," said lead ...

Some Arthritis Meds Cost Seniors Thousands Annually

Posted 21 Apr 2015 by Drugs.com

TUESDAY, April 21, 2015 – Arthritis medications known as biologic disease-modifying drugs can cost Medicare patients more than $2,700 in co-payments a year, a new report finds. Researchers say the tab is an immense burden on patients with disabling conditions such as rheumatoid arthritis, a chronic disorder that affects an estimated 1.3 million Americans. Biologic anti-rheumatic medications – ...

Hairless Man Now Hairy, Thanks to Arthritis Drug Xeljanz

Posted 22 Jun 2014 by Drugs.com

FRIDAY, June 20, 2014 – A man with a rare condition that left him with no hair on his body grew a full head of hair after taking an arthritis drug, a new study reveals. The 25-year-old patient also grew eyebrows and eyelashes, along with facial, armpit and other hair after treatment with tofacitinib citrate. The man's lack of body hair was caused by a disease called alopecia universalis. The ...

Ask a Question

Further Information

Related Condition Support Groups

Rheumatoid Arthritis, Ulcerative Colitis, Psoriatic Arthritis

Xeljanz Patient Information at Drugs.com